Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$48.90 USD

48.90
2,119,364

-0.26 (-0.53%)

Updated Aug 27, 2026 04:00 PM ET

After-Market: $48.92 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug

by Zacks Equity Research

Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.

Zacks Equity Research

Are Investors Undervaluing Alkermes (ALKS) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

by Zacks Equity Research

Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.

Zacks Equity Research

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal

by Zacks Equity Research

Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.

Zacks Equity Research

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

by Zacks Equity Research

INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.

Sanghamitra Saha headshot

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

by Sanghamitra Saha

Top-ranked stocks TakeTwo Interactive Software (TTWO), Allstate (ALL), SoFi Technologies (SOFI), Alkermes (ALKS) and Morgan Stanley (MS) are likely to beat on the bottom line in their upcoming releases.

Zacks Equity Research

BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU

by Zacks Equity Research

Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms

Zacks Equity Research

RHHBY Reports Positive Phase III Data on Breast Cancer Drug

by Zacks Equity Research

Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.

Zacks Equity Research

JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data

by Zacks Equity Research

Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.